MA45245A - Méthode de traitement de maladie intestinale inflammatoire - Google Patents

Méthode de traitement de maladie intestinale inflammatoire

Info

Publication number
MA45245A
MA45245A MA045245A MA45245A MA45245A MA 45245 A MA45245 A MA 45245A MA 045245 A MA045245 A MA 045245A MA 45245 A MA45245 A MA 45245A MA 45245 A MA45245 A MA 45245A
Authority
MA
Morocco
Prior art keywords
treatment
intestinal disease
inflammatory intestinal
inflammatory
disease
Prior art date
Application number
MA045245A
Other languages
English (en)
French (fr)
Inventor
Morris Barocas
Marc R Gastonguay
Maria Rosario
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA45245A publication Critical patent/MA45245A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA045245A 2016-06-12 2017-06-12 Méthode de traitement de maladie intestinale inflammatoire MA45245A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662349026P 2016-06-12 2016-06-12

Publications (1)

Publication Number Publication Date
MA45245A true MA45245A (fr) 2019-04-17

Family

ID=59270123

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045245A MA45245A (fr) 2016-06-12 2017-06-12 Méthode de traitement de maladie intestinale inflammatoire

Country Status (7)

Country Link
US (1) US11389533B2 (enExample)
EP (1) EP3468597A1 (enExample)
JP (1) JP7202893B2 (enExample)
CN (1) CN109414502A (enExample)
CA (1) CA3027286A1 (enExample)
MA (1) MA45245A (enExample)
WO (1) WO2017218434A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US20240254243A1 (en) * 2021-06-17 2024-08-01 Prometheus Laboratories Inc. Systems and methods for improved targeted therapy
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
JPWO2002078779A1 (ja) 2001-03-27 2004-07-22 日本ゼオン株式会社 医療用ガイドワイヤ
EP1784426B1 (en) 2004-09-03 2011-11-23 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
US20070122404A1 (en) 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
LT2704742T (lt) * 2011-05-02 2017-10-25 Millennium Pharmaceuticals, Inc. Anti-alfa4beta7 antikūno kompozicija
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en) * 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US20170360926A1 (en) 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
MX392140B (es) 2015-06-08 2025-03-21 Univ Washington Composiciones y uso de las mismas para tratar la enfermedad celiaca.
KR102710759B1 (ko) 2016-03-14 2024-09-25 밀레니엄 파머슈티컬스 인코퍼레이티드 이식편대숙주 질환을 예방하는 방법
CA3017758A1 (en) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
MA44864A (fr) 2016-05-04 2019-03-13 Icahn School Med Mount Sinai Trithérapie pour le traitement d'une maladie intestinale inflammatoire

Also Published As

Publication number Publication date
CN109414502A (zh) 2019-03-01
US11389533B2 (en) 2022-07-19
WO2017218434A1 (en) 2017-12-21
US20190255172A1 (en) 2019-08-22
JP7202893B2 (ja) 2023-01-12
JP2019519544A (ja) 2019-07-11
EP3468597A1 (en) 2019-04-17
CA3027286A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
MA46771A (fr) Méthode de traitement de tumeur immunothérapeutique
EP3380121A4 (en) METHOD FOR THE TREATMENT OF EYE DISEASES
EP3515505A4 (en) AAV TREATMENT BY MORBUS ALZHEIMER
EP2971127A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF INFLAMMABLE ENDURANCE
EP3488001A4 (en) TREATMENT OF CANCER
EP3463350A4 (en) METHOD FOR TREATING LIVER FIBROSE
EP3341080A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP3843716A4 (en) METHODS OF TREATMENT OF LYSOSOMAL STORAGE DISEASES
FR25C1031I1 (fr) Traitement de maladies cholestatiques intrahepatiques
EP3490582A4 (en) METHOD AND COMPOSITIONS FOR TREATING MYELOFIBROSE
EP3820461A4 (en) METHODS OF TREATMENT OF CANCER
EP3658139A4 (en) Methods for treating liver diseases
EP3291815A4 (en) METHOD FOR TREATING A NEURODEEGENERATIVE DISEASE
EP3294345A4 (en) TPP1 FORMULATIONS AND METHOD FOR THE TREATMENT OF CLN2 DISEASES
EP3522934A4 (en) COMPOSITIONS AND METHODS FOR TREATING KIDNEY DISEASES
EP3455188C0 (de) Verfahren zur behandlung von schlacke
MA41462A (fr) Méthode de traitement de maladies
EP3375440A4 (en) METHOD FOR THE TREATMENT OF MUCOSITIS
EP3448365A4 (en) METHOD FOR TREATING CONSTRUCTION
EP3307280A4 (en) TREATMENT OF SEXUAL DYSFUNCTION
MA48862A (fr) Méthode de traitement de tumeur immunothérapeutique
EP3703707A4 (en) METHOD FOR TREATMENT OF ACID-BASE DISORDER
EP3422943A4 (en) METHOD FOR THE TREATMENT OF MEDICINAL TOXICATION
MA41636A (fr) Méthode de traitement de la cholangite sclérosante primitive
MA47395A (fr) Méthode pour le traitement d'une maladie neurologique